Gilead Is First Splash In HIV Patent Pool; Five Other Firms In Negotiations
This article was originally published in The Pink Sheet Daily
Gilead's deal with the Medicines Patent Pool limits the developing countries that have access to generics and requires that the drugs be manufactured in India.
You may also be interested in...
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries
The drug purchasing group UNITAID may succeed in getting pharmaceutical companies to pool patents on their AIDS medicines. So far, it has won buy-in of the idea from three: Gilead Sciences, Merck and Johnson & Johnson subsidiary Tibotec
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.